BRIEF published on 04/07/2026 at 07:05, 6 months 28 days ago Aelis Farma obtient une subvention de 458 000 € pour son programme de lutte contre l'obésité France 2030 Aelis Farma Récepteur CB1 Recherche Sur L'obésité Subvention De Nouvelle-Aquitaine
BRIEF published on 04/07/2026 at 07:05, 6 months 28 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 6 months 28 days ago Informations privilégiées / Autres communiqués Aelis Farma reçoit 458 k€ de subvention de France 2030 en Nouvelle-Aquitaine pour son programme innovant dans l'obésité et les maladies métaboliques. Soutien non dilutif pour la recherche sur les traitements des désordres métaboliques Subvention France 2030 Obésité Aelis Farma Nouvelle-Aquitaine
PRESS RELEASE published on 04/07/2026 at 07:00, 6 months 28 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 7 months 15 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
BRIEF published on 03/21/2026 at 10:10, 7 months 15 days ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
PRESS RELEASE published on 03/21/2026 at 10:05, 7 months 15 days ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
PRESS RELEASE published on 03/21/2026 at 10:05, 7 months 15 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 9 months 24 days ago Aelis Farma obtient un avis favorable de l'EMA pour AEF0217 dans la trisomie 21 EMA Aelis Farma Trisomie 21 AEF0217 Développement Pédiatrique
BRIEF published on 01/12/2026 at 07:35, 9 months 24 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
Published on 11/05/2026 at 15:20, 33 minutes ago MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors
Published on 11/05/2026 at 14:31, 1 hour 22 minutes ago First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
Published on 11/05/2026 at 14:25, 1 hour 28 minutes ago Polaris Renewable Energy Announces Q3 2026 Results
Published on 11/05/2026 at 14:20, 1 hour 33 minutes ago Polaris Renewable Energy Declares Quarterly Dividend
Published on 11/05/2026 at 14:15, 1 hour 38 minutes ago Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook
Published on 11/05/2026 at 15:34, 18 minutes ago Finexity AG: NuWays and GBC confirm price targets following Capital Markets Day and 9-month figures, taking the share split into account
Published on 11/05/2026 at 15:10, 42 minutes ago Center for Creative Leadership Names Patrick Mullane President and Chief Executive Officer
Published on 11/05/2026 at 14:58, 55 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/05/2026 at 15:01, 51 minutes ago Chiffre d'Affaires du 1er semestre de l'exercice 2026/2027
Published on 11/05/2026 at 10:16, 5 hours 36 minutes ago Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 10:16, 5 hours 36 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
